share_log

邁博藥業-B:內幕消息公告秘魯衛生部批准核心產品CMAB008(注射用英夫利西單抗)的上市註冊申請

MABPHARM-B: INSIDE INFORMATION ANNOUNCEMENTAPPROVAL FROM THE MINISTRY OF HEALTH OF PERUON THE NEW DRUG APPLICATION (NDA)OF OUR CORE PRODUCT, CMAB008 (INFLIXIMAB FOR INJECTION)

HKEX ·  Jul 2 18:09

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.